Celyad Oncology S.A.
CYAD.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 82.4% | – | – | – |
| Cost of Goods Sold | -€1 | €0 | €1 | €2 |
| Gross Profit | €1 | €0 | -€1 | -€2 |
| % Margin | 494.1% | 32.4% | – | – |
| R&D Expenses | €3 | €5 | €18 | €19 |
| G&A Expenses | €3 | €6 | €10 | €10 |
| SG&A Expenses | €4 | €6 | €10 | €10 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €0 | -€2 | €0 | €0 |
| Operating Expenses | €7 | €8 | €28 | €29 |
| Operating Income | -€6 | -€11 | -€29 | -€26 |
| % Margin | -3,365.1% | -10,389.2% | – | – |
| Other Income/Exp. Net | €0 | €2 | -€12 | -€0 |
| Pre-Tax Income | -€6 | -€9 | -€41 | -€27 |
| Tax Expense | -€0 | -€0 | €0 | €0 |
| Net Income | -€6 | -€8 | -€41 | -€27 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| Weighted Avg Shares Out | 41 | 26 | 23 | 16 |
| Weighted Avg Shares Out Dil | 41 | 26 | 23 | 16 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €1 | €1 | €2 |
| EBITDA | -€5 | -€8 | -€40 | -€25 |
| % Margin | -2,898.4% | -7,610.8% | – | – |